Growth Metrics

Soleno Therapeutics (SLNO) Gross Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Gross Margin for 4 consecutive years, with 99.06% as the latest value for Q4 2025.

  • For Q4 2025, Gross Margin changed N/A year-over-year to 99.06%; the TTM value through Dec 2025 reached 99.27%, changed N/A, while the annual FY2025 figure was 98.58%, N/A changed from the prior year.
  • Gross Margin hit 99.06% in Q4 2025 for Soleno Therapeutics, up from 98.27% in the prior quarter.
  • Across five years, Gross Margin topped out at 99.06% in Q4 2025 and bottomed at 97.87% in Q2 2025.